drugset / Trial / NCT02866032

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

NCT02866032

Phase 3 Completed 452 enrolled Moberg Pharma AB

Summary

The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.

Timeline

Start
2016-09
Primary completion
2020-06-10
Completion
2020-06-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ciclopirox Unknown 80 unknown
Subject MOB015B Unknown Topical

Indications